Ken Griffin Arcutis Biotherapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $271,050 - $981,618	83,400 Added 158.25%	136,100 $1.35 Million
Q4 2023 Feb 14, 2024	BUY	$1.84 - $4.82 $51,704 - $135,442	28,100 Added 114.23%	52,700 $170,000
Q3 2023 Nov 14, 2023	BUY	$5.31 - $10.98 $22,833 - $47,214	4,300 Added 21.18%	24,600 $130,000
Q2 2023 Aug 14, 2023	BUY	$7.51 - $15.0 $86,365 - $172,500	11,500 Added 130.68%	20,300 $193,000
Q1 2023 May 15, 2023	SELL	$10.23 - $17.14 $3,069 - $5,142	-300 Reduced 3.3%	8,800 $96,000

Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $127,036 - $185,640	9,100 New	9,100 $134,000

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $578M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.